Mesenchymal Stromal Cells : an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases
There is an urgent need for new antimicrobial strategies for treating complex infections and emerging pathogens. Human mesenchymal stromal cells (MSCs) are adult multipotent cells with antimicrobial properties, mediated through direct bactericidal activity and modulation of host innate and adaptive immune cells. More than 30 in vivo studies have reported on the use of human MSCs for the treatment of infectious diseases, with many more studies of animal MSCs in same-species models of infection. MSCs demonstrate potent antimicrobial effects against the major classes of human pathogens (bacteria, viruses, fungi, and parasites) across a wide range of infection models. Mechanistic studies have yielded important insight into their immunomodulatory and bactericidal activity, which can be enhanced through various forms of preconditioning. MSCs are being investigated in over 80 clinical trials for difficult-to-treat infectious diseases, including sepsis and pulmonary, intra-abdominal, cutaneous, and viral infections. Completed trials consistently report MSCs to be safe and well tolerated, with signals of efficacy against some infectious diseases. Although significant obstacles must be overcome to produce a standardized, affordable, clinical-grade cell therapy, these studies suggest that MSCs may have particular potential as an adjunct therapy in complex or resistant infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Clinical microbiology reviews - 34(2021), 4 vom: 15. Dez., Seite e0006421 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shaw, Timothy D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.02.2022 Date Revised 07.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/CMR.00064-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33153729X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33153729X | ||
| 003 | DE-627 | ||
| 005 | 20231225213703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/CMR.00064-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM33153729X | ||
| 035 | |a (NLM)34612662 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shaw, Timothy D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mesenchymal Stromal Cells |b an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2022 | ||
| 500 | |a Date Revised 07.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a There is an urgent need for new antimicrobial strategies for treating complex infections and emerging pathogens. Human mesenchymal stromal cells (MSCs) are adult multipotent cells with antimicrobial properties, mediated through direct bactericidal activity and modulation of host innate and adaptive immune cells. More than 30 in vivo studies have reported on the use of human MSCs for the treatment of infectious diseases, with many more studies of animal MSCs in same-species models of infection. MSCs demonstrate potent antimicrobial effects against the major classes of human pathogens (bacteria, viruses, fungi, and parasites) across a wide range of infection models. Mechanistic studies have yielded important insight into their immunomodulatory and bactericidal activity, which can be enhanced through various forms of preconditioning. MSCs are being investigated in over 80 clinical trials for difficult-to-treat infectious diseases, including sepsis and pulmonary, intra-abdominal, cutaneous, and viral infections. Completed trials consistently report MSCs to be safe and well tolerated, with signals of efficacy against some infectious diseases. Although significant obstacles must be overcome to produce a standardized, affordable, clinical-grade cell therapy, these studies suggest that MSCs may have particular potential as an adjunct therapy in complex or resistant infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a antimicrobial | |
| 650 | 4 | |a cell therapy | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a host-directed therapy | |
| 650 | 4 | |a immunomodulation | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a mesenchymal stromal cells | |
| 650 | 4 | |a pathogens | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Krasnodembskaya, Anna D |e verfasserin |4 aut | |
| 700 | 1 | |a Schroeder, Gunnar N |e verfasserin |4 aut | |
| 700 | 1 | |a Zumla, Alimuddin |e verfasserin |4 aut | |
| 700 | 1 | |a Maeurer, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a O'Kane, Cecilia M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology reviews |d 1996 |g 34(2021), 4 vom: 15. Dez., Seite e0006421 |w (DE-627)NLM012914312 |x 1098-6618 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2021 |g number:4 |g day:15 |g month:12 |g pages:e0006421 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/CMR.00064-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2021 |e 4 |b 15 |c 12 |h e0006421 | ||